Dengue virus serotype 1 polyprotein (DENV-1 antigens)

Dengue virus serotype 1 (DENV-1) antigens are the protein components of the DENV-1 virus, primarily the structural proteins (Envelope, Membrane, and Capsid) and non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (UniProt: P17763). The Envelope (E) protein is the major surface glycoprotein responsible for host cell receptor binding and membrane fusion, serving as the primary target for neutralizing antibodies (PubMed: 26735133). Non-structural protein 1 (NS1) is a secreted glycoprotein involved in viral replication and immune evasion, and it is a key diagnostic biomarker for early infection (CDC, 2023). DENV-1 is one of four serotypes causing dengue fever, which can progress to severe dengue hemorrhagic fever or shock syndrome (WHO, 2023). Therapeutic development focuses on tetravalent vaccines like Dengvaxia and Qdenga to elicit broad immunity, as well as monoclonal antibodies and small-molecule inhibitors targeting the NS3 protease or NS5 polymerase (Nature Reviews Drug Discovery, 2020). A significant challenge in targeting these antigens is antibody-dependent enhancement (ADE), where non-neutralizing antibodies facilitate viral entry into Fc-receptor-bearing cells, potentially increasing disease severity (PubMed: 28165445). Small molecule inhibitors like JNJ-1802 are currently being investigated for their ability to block the interaction between non-structural proteins, thereby preventing viral replication (ClinicalTrials.gov, 2023).

Other names

DENV-1 proteinsDengue virus type 1 antigensDengue virus 1 polyprotein

Vaccines induce neutralizing antibodies and T-cell responses against structural and non-structural proteins; monoclonal antibodies neutralize the Envelope protein to prevent viral entry; small molecules inhibit non-structural proteins like NS3 or NS5 to block viral replication.